RetinalGeniX Technologies Inc. announced that it has contracted with Avania CRO to provide guidance for the Company?s interactions with the FDA for the development of RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and RTG-2024 for the treatment of Alzheimer?s syndrome dementia, and the RetinalCam? image visualization device. Overall, RetinalGeniX now has advisors for each of its three components of precision ophthalmology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 USD | +12.90% |
|
-.--% | +13.27% |
1st Jan change | Capi. | |
---|---|---|
+13.27% | 62.51M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- RTGN Stock
- News RetinalGenix Technologies Inc.
- RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device